161 related articles for article (PubMed ID: 20361090)
61. Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm.
Peyro-Saint-Paul H; Hermitte F
Blood; 2010 Sep; 116(11):1994-5. PubMed ID: 20847214
[No Abstract] [Full Text] [Related]
62. Multiple thrombophilic factors in a patient with Budd-Chiari syndrome.
Brancaccio V; Iannaccone L; Margaglione M; Guardascione MA; Amitrano L
Clin Lab Haematol; 2002 Feb; 24(1):61-3. PubMed ID: 11843901
[TBL] [Abstract][Full Text] [Related]
63. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
[TBL] [Abstract][Full Text] [Related]
64. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.
Qi X; Zhang C; Han G; Zhang W; He C; Yin Z; Liu Z; Bai W; Li R; Bai M; Yang Z; Wu K; Fan D
J Gastroenterol Hepatol; 2012 Jun; 27(6):1036-43. PubMed ID: 22142461
[TBL] [Abstract][Full Text] [Related]
65. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
66. The JAK2 V617F mutation in pediatric myeloproliferative neoplasms: how and when?
Langabeer SE; Smith OP; McMahon C
Pediatr Hematol Oncol; 2014 Mar; 31(2):138-9. PubMed ID: 24383477
[No Abstract] [Full Text] [Related]
67. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
Brière JB
Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
[TBL] [Abstract][Full Text] [Related]
68. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
69. The recent advances in classic BCR-ABL-negative myeloproliferative disorders.
Tefferi A
Clin Adv Hematol Oncol; 2007 Feb; 5(2):113-5. PubMed ID: 17344799
[No Abstract] [Full Text] [Related]
70. Myeloproliferative neoplasms.
Kim J; Haddad RY; Atallah E
Dis Mon; 2012 Apr; 58(4):177-94. PubMed ID: 22449367
[No Abstract] [Full Text] [Related]
71. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
[No Abstract] [Full Text] [Related]
72. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
73. Myelodysplastic/myeloproliferative disorders.
Malcovati L; Cazzola M
Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
[No Abstract] [Full Text] [Related]
74. Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.
Le Bars H; Boulland ML; Bareau B; Grosbois B; Corolleur M; Lamy T; Fardel O
Int J Lab Hematol; 2010 Aug; 32(4):458-60. PubMed ID: 20331762
[No Abstract] [Full Text] [Related]
75. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
76. Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Gianotti R; Charles H; Hymes K; Chandarana H; Sigal S
World J Gastroenterol; 2014 Oct; 20(39):14495-9. PubMed ID: 25339837
[TBL] [Abstract][Full Text] [Related]
77. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
78. Budd-Chiari syndrome and factor V Leiden mutation.
Mahmoud AE; Wilde JT; Elias E
Lancet; 1995 Feb; 345(8948):526. PubMed ID: 7861905
[No Abstract] [Full Text] [Related]
79. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
Qian J; Lin J; Yao DM; Chen Q; Xiao GF; Ji RB; Li Y; Yang J; Qian Z
Clin Chim Acta; 2010 Dec; 411(23-24):2097-100. PubMed ID: 20728437
[TBL] [Abstract][Full Text] [Related]
80. Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective.
Cantoni S; Colombo C; Soriano F; Oreglia JA; Sacco A; Veronese S; Brunelli D; Rubboli A; Morici N
Thromb Haemost; 2022 Aug; 122(8):1429-1431. PubMed ID: 35038762
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
